Regeneron Reports Positive Phase 1/2 LINKER-AL2 Data For Lynozyfic In Treating Amyloidosis

Regeneron Pharmaceuticals Inc. (REGN), a biotechnology company, on Thursday released positive Phase 1/2 LINKER-AL2 results for Lynozyfic in the treatment of second line-plus systemic amyloid light chain (AL) amyloidosis.